Introduction {#S0001}
============

Sepsis is defined as an organic dysfunction that threatens life, caused by an exacerbated response to an infection.[@CIT0001],[@CIT0002] It implies the failure of multiple organs, including the kidneys.[@CIT0003]--[@CIT0005] As such, the adoption of measures that lead to decreased mortality and reduced costs related to treatment and hospitalization, such as early administration of antimicrobials, the choice of which should be based on the patient's history, the recent use of antibiotics and the origin of the pathogens (community or hospital), are justified.[@CIT0006]

The main polemic points on vancomycin relate to its efficacy and safety.[@CIT0005]--[@CIT0009] Regarding efficacy, the concern is the alteration in pharmacokinetics, usually related to the distribution, metabolism, and elimination of the drug,[@CIT0006],[@CIT0008] which can lead to subtherapeutic concentrations, leading to the emergence of bacterial resistance due to the inefficacy of the treatment and consequently leading to higher mortality. Regarding safety, emphasis has been given to the main side effect of the medication --- nephrotoxicity --- which can aggravate the clinical picture and contribute to unfavorable outcomes.

Based on studies of animal and clinical experimentation, in 2009 it was determined that optimum activity occurs with an area under the curve divided by the minimum inhibitory concentration value of equal or greater than 400. It was identified that this value is reached when trough serum concentrations of vancomycin (when the medicine is at a lower concentration) is 15--20 mg/L for major infections.[@CIT0010],[@CIT0011] However, there have been few studies to evaluate monitoring of its serum concentration and association with clinical outcomes, requiring improvement in knowledge regarding the safe and effective use of vancomycin.

Methodology {#S0002}
===========

This was a prospective observational cohort study of adult patients diagnosed with sepsis defined using the quick SOFA[@CIT0002] and admitted to four wards at the Clinics Hospital of Botucatu Medical School (two clinical and two surgical) during August 2016 to July 2017. Vancomycin was used according to the institution's protocols: loading dose of 25 mg/kg and maintenance of 15 mg/kg, with dosing intervals of 12/12--96/96 hours, depending on the serum concentration of the antimicrobial. We excluded patients aged \<18 years, pregnant patients, those with chronic kidney disease stage 5 (classified according to estimated serum-creatinine clearance or measured at \<15 mL/min), renal transplant recipients, patients already admitted with an acute kidney injury (AKI) of any etiology, vancomycin use \<48 hours, and those who had developed AKI from another etiology (prerenal or ischemic, glomerular, and vascular renal causes).

The study was approved by the local research ethics committee and registered in the Brazilian Registry of Clinical Trials (ReBEC) under number RBR-4zrwtz. Patients or legal guardians signed the informed consent form. From the time of prescription of vancomycin, the patient was included in the study and their electronic medical record consulted, and daily evolution data obtained, always by the same observer, until the end of the use of vancomycin and its hospital outcome (discharge or death).

The AKI definitions used were those of the organization Kidney Disease: Improving Global Outcomes (KDIGO):[@CIT0005] baseline creatinine being the lowest value in 6 months if no prior data available or lower creatinine levels during hospitalization as long as the patient was not on dialysis. Therapeutic, subtherapeutic, and toxic serum concentrations were defined as two consecutive trough concentrations of 15--20 mg/L, \<15 mg/L, and \>20 mg/L, respectively.

Central tendency and dispersion were calculated as continuous and frequency values for the categorical variable and occurrence of AKI and death were established as dependent variables. ROC curves were built to evaluate the cutoff points for serum-vancomycin concentration as predictors of diagnosis and prognosis of AKI during T0--T2, T2--T4, and T4--T6. Areas under the curve of 0.7--0.79 were considered satisfactory and 0.8--0.89 as optimum. Sample-size calculation was performed using Lee\'s formula, and considering that the prevalence of AKI would be 20% higher in patients with toxic concentrations of vancomycin, with *α*-error of 0.05 and 80% study power, 64 patients were estimated for each group (total 128: 64 with toxic concentrations and 64 without).

Results {#S0003}
=======

We included 135 patients from clinical and surgical wards ([Figure 1](#F0001){ref-type="fig"}), of which 94.1% had serum concentrations of vancomycin measured during the use of the antimicrobial. Of these, 75.6% received adjustments in dosage and 59.3% presented a toxic serum concentration of vancomycin. The mean higher value for serum concentration was 22.07±14.77mg/L, 27.4% of the patients presented with AKI, of which KDIGO stage 1 was the most frequent (54.05%), and 20.7% evolved to death.Figure 1Flow diagram of patients included and excluded.

[Table 1](#T0001){ref-type="table"} presents clinical and laboratory characteristics of the patients and [Table 2](#T0002){ref-type="table"} vancomycin-related characteristics, both regarding the presence of absence of AKI. n Cox regression analysis, serum concentration of vancomycin during 96--144 hours (T4--T6, HR 1.06; *p*=0.038) was identified as the only risk factor for AKI, as indicated in [Table 3](#T0003){ref-type="table"}. The rest of the variables did not present statistically significant differences between the groups.Table 1Clinical and Laboratory Characteristics of Patients Using Vancomycin Hospitalized in Surgical and Clinical Wards Regarding the Presence or Absence of AKIGeneralwith AKIWithout AKI*p*-value(n=135)(n=37)(n=98)Age (years)\*56.12±17.3556.03±17.556.1±17.30.836**Weight (kg)\*65±16.472.3±16.865.6±15.80.036**Male sex (%)93 (68.9)28 (75.6)65 (66.3)0.402GFR baseline (CKD-EPI), mL/min\*106±25.7106.6±28.4108.5±24.70.811Arterial hypertension (%)62 (45.9)15 (40.5)47 (47.9)0.563Diabetes mellitus (%)44 (32.6)13 (35.13)31 (31.63)0.856CKD (%)4 (3)1 (2.7)3 (3.06)1CVD (%)14 (10.4)4 (10.81)10 (10.2)1**Mechanical ventilation (%)12 (8.9)10 (27.03)2 (2.04)\<0.001Vasoactive drugs (%)11 (8.1)7 (18.9)4 (4.08)0.014**Contrast (%)21 (15.6)6 (16.2)15 (15.3)1**Diuretic (%)33 (24.4)17 (45.9)16 (16.3)0.001**Other nephrotoxic drugs (%)18 (13.3)8 (21.62)10 (10.2)0.145Hospitalization category0.36 Surgical (%)70 (51.9)19 (51.3)51 (52.04) Clinical (%)65 (48.1)32 (49.5)33 (50.8)Hospitalization diagnostic **Infection (%)76 (53.6)15 (40.5)61 (62.2)0.038** Cardiovascular (%)5 (3.7)3 (8.1)2 (2.04)0.248 Postoperative (%)28 (20.7)8 (21.62)20 (20.4)1 Other (%)26 (19.3)11 (29.73)15 (15.3)---Infection focus Cutaneous (%)53 (39.3)14 (37.8)39 (39.7)0.992 Urine (%)5 (3.7)---5 (5.1)0.374 Blood (%)4 (3)---4 (4.08)0.497 Lungs (%)27 (20)9 (24.3)18 (18.3)0.596 Central nervous system (%)21 (15.6)6 (16.2)15 (15.3)1 Undetermined (%)25 (18.4)6 (16.2)19 (19.3)0.92 Hospitalization time (days)\*22±16.229.9±17.824.27±15.30.053**Death (%)28 (20.7)14 (37.8)14 (14.2)0.006**[^1] Table 2Characteristics Related to the Use of Vancomycin in Hospitalized Patients in Clinical and Surgical Wards Regarding the Presence or Absence of AKIVariablesGeneralwith AKIWithout AKI*p*-value(n=135)(n=37)(n=98)Vancomycin usage (days)\*11±7.413.14±7.712.3±7.30.478**Absolute attack dosage (mg)\*1,500±394.41,651.3±320.41,513.01±414.10.031**Attack dosage (mg/kg)\*24.3±6.223.9±5.523.3±6.60.27**Mean maintenance dosage (mg/kg)\*16.9±5.618.6±5.516.2±5.60.047**Dose adjustment (%)102 (75.6)32 (86.4)70 (71.4)0.112**Number of dose adjustments\*2±1.62.38±1.71.6±1.580.021Toxic serum concentration (%)80 (59.3)32 (86.4)48 (48.9)\<0.001**Subtherapeutic serum concentration (%)75 (55.6)17 (45.9)58 (59.1)0.235**Higher value of vancomycin (mg/L)\*22.07±14.732.6±17.320.8±12.3\<0.001**Vancomycin T0--T2 (mg/L)\*13.14±6.918.60±8.110.85±5.20.09Vancomycin T2--T4 (mg/L)\*11.9±11.616.1±15.211.3±10.180.138**Vancomycin T4--T6 (mg/L)\*17.93±7.9421.52±7.3816.50±7.770.014Vancomycin T6--T8 (mg/L)\*21.33±10.9728.83±11.1817.95±7.140.008**Number of collected serum concentrations\*4±3.0344.46±3.073.77±3.0150.171[^2] Table 3Cox Regression of Variables Associated with the Presence of AKI in Patients Using Vancomycin Hospitalized in Clinical and Surgical WardsVariablesHRCI*p*-valueNumber of adjustments1.170.91--1.50.21Vasoactive drug1.0040.96--1.20.953Mechanical ventilation1.0070.97--1.1180.947Attack dosage (mg)1.0011.000--1.0020.87**Vancomycin T4--T6 (mg/L)1.0641.003--1.1280.038**[^3]

ROC-curve analysis ([Figure 2](#F0002){ref-type="fig"}) showed that serum concentration \>21.5 mg/L between the fourth and sixth days was a good predictor of AKI, with area under the curve of 0.8 (95% CI 0.62--0.98), sensitivity of 81.1%, specificity of 73.7%, and preceding diagnosis of AKI by at least 3 days (AKI happened on average at the ninth day of vancomycin use). After construction of the free time curve for AKI, based on cutoff values obtained by the ROC curve fort 4--6 days, it was observed that in the group with serum concentrations \> 21.5 mg/L, the free time for the development of AKI was smaller than the group with serum concentrations \<21.5 mg/L (log rank 0.026, [Figure 3](#F0003){ref-type="fig"}).Figure 2ROC curve for AKI outcome in septic patients using vancomycin hospitalized in clinical and surgical wards. T0--T2, serum concentration between the start and second day of usage of vancomycin (0--48 hours); T2--T4, serum concentration between the second and fourth days of usage of vancomycin (48--96 hours); T4--T6, serum concentration between the fourth and sixth days of usage of vancomycin (96--144 hours); T6--T8, serum concentration between the sixth and eighth days of usage of vancomycin (144--192 hours).Figure 3Free time for acute kidney injury (AKI) according to serum concentration (cutoff 21.5 mg/L) during T4--T6 days (96--144 hours) for use of vancomycin in septic patients in clinical and surgical wards.

[Table 4](#T0004){ref-type="table"} presents clinical and laboratory characteristics of patients and [Table 5](#T0005){ref-type="table"} characteristics related to vancomycin, both regarding the outcome of death. After analysis of both groups through Cox regression, it was observed that serum concentration of vancomycin between the fourth and sixth days (HR 1,078, *p*=0.039), was the sole predictor of death, as shown in [Table 6](#T0006){ref-type="table"}. After construction of the free time curve for death, based on the cutoff values obtained by the ROC curve for 4--6 days, it was observed that free time for death was smaller for the group with serum concentration \>21.5 mg/L than the group with serum concentration \<21.5 mg/L (log rank 0.006, [Figure 4](#F0004){ref-type="fig"}).Table 4Clinical and Laboratory Characteristics of Patients Using Vancomycin Hospitalized in Clinical and Surgical Wards According to OutcomesGeneralNo DeathDeath*p-*value(n=135)(n=107)(n=28)Age (years)\*60±17.354.8±17.261.1±17.10.061Weight (kg)\*65±16.467.3±16.268.4±17.40.783Male sex (%)93 (68.9)71 (66.3)22 (78.5)0.311GFR baseline (CKD-EPI)\*106±25.7108.8±23.7104.6±25.70.296Arterial hypertension (%)62 (45.9)47 (43.9)15 (53.5)0.485Diabetes mellitus (%)44 (32.6)39 (36.4)5 (17.8)0.101CKD (%)4 (3)3 (2.8)1 (3.5)1CVD (%)14 (10.4)8 (7.5)6 (21.4)0.071Mechanical ventilation (%)12 (8.9)7 (6.5)5 (17.8)0.134**Vasoactive drugs (%)11 (8.1)5 (4.6)6 (21.4)0.013**Contrast (%)21 (15.6)19 (17.7)2 (7.1)0.277Diuretic (%)33 (24.4)24 (22.4)9 (32.1)0.414Other nephrotoxic drugs ^\#^(%)18 (13.3)14 (13.08)4 (14.2)1Hospitalization unit0.003 **Clinical (%)65 (48.1)44 (41.1)21 (75)**--- **Surgical (%)70 (51.9)63 (58.8)7 (25)**---Hospitalization diagnostic Infection (%)76 (53.6)60 (56.07)16 (57.1)1.00 Cardiovascular (%)5 (3.7)2 (1.8)3 (10.7)0.100 Postoperative (%)28 (20.7)25 (23.36)3 (10.7)0.227 Other (%)26 (19.3)Infection focus Urine (%)5 (3.7)4 (3.7)1 (3.5)1.00 Blood (%)4 (3)4 (3.7)00.680 **Lungs (%)27 (20)16 (14.9)11 (39.2)0.009** Abdomen (%)6 (4.4)4 (3.7)2 (7.1)0.616 Undetermined (%)15 (11.1)11 (10.2)4 (14.2)0.510**Nephrological segment (%)13 (9.6)7 (6.5)6 (21.4)0.044**Hospitalization time (days)\*22±16.226.09±16.324.8±15.90.658**AKI (%)37 (27.4)23 (21.5)14 (50)0.006**KDIGO (%) 121 (56.7)16 (69.6)5 (35.7)0.09 27 (19)4 (17.4)3 (21.4)0.316 **39 (24.3)3 (13)6 (42.8)0.05**[^4] Table 5Characteristics Related to the Use of Vancomycin in Hospitalized Patients on Surgical and Clinical Wards Regarding OutcomeGeneralNo DeathDeath*p*-value(n=135)(n=107)(n=28)**Time of usage of vancomycin (days)\*11±7.413.3±7.59.5±6.070.016**Absolute attack dosage (mg)\*1,500±394.41,554.6±407.11,536.6±347.90.962Attack dosage (mg/kg)\*24.311±6.323.52±6.423.59±6.020.847Mean maintenance dose (mg/kg)\*16.9±5.718.02±5.517.6±6.50.422Dose adjustment (%)102 (75.6)82 (76.6)20 (71.4)0.746Number of dose adjustments\*2±1.61.8±1.61.9±1.70.87Toxic serum concentrations (%)80 (59.3)62 (57.9)18 (64.2)0.695Subtherapeutic serum concentrations (%)75 (55.6)61 (57.01)14 (50)0.652Higher serum concentrations (mg/L)\*22.07±14.723.3±13.827.06±17.80.229Vancomycin T0--T2 (mg/L)\*13.1±6.912.3±6.918.03±6.90.324Vancomycin T2--T4 (mg/L)\*11.6±11.911.9±10.215.3±16.80.677**Vancomycin T4--T6 (mg/L)\*17.9±7.916.5±7.122.7±9.10.005**Vancomycin T6--T8 (mg/L)\*9.29±11.99.96±11.76.71±12.50.064Number of collected serum concentrations\*4±3.034.07±3.043.54±3.020.29[^5] Table 6Cox Regression of Variables Associated with Death in Patients Using Vancomycin Hospitalized in Clinical and Surgical WardsHRCIp-valueDiabetes mellitus2.4340.637--9.2940.193SOFA score1.1690.99--1.380.066**Serum concentration, T4--T6 days (mg/L)1.0781.004--1.1570.039**Age0.9920.959--1.0250.63Follow-up with nephrologist (due to AKI)0.9340.243--3.5840.92[^6][^7] Figure 4Free time for death outcome according to serum concentration (cutoff 21.5 mg/L) during T4--T6 for vancomycin in patients hospitalized in surgical and clinical wards. T4--T6, serum concentration between the fourth and sixth days of usage of vancomycin (96--144 hours).

Discussion {#S0004}
==========

Despite vancomycin\'s ample use in clinical practice, two concerns still permeate its use: efficacy and safety. Regarding efficacy, it is known that there are alterations in the pharmacokinetics of septic patients, which may lead to subtherapeutic serum concentrations and emergence of bacterial resistance, with a possible increase in mortality. Regarding safety, focus has been put on its main collateral effect, nephrotoxicity, with risks of AKI and complications on the short and long term.

This cohort study had as an objective to evaluate the prevalence of monitorization of serum concentrations at adequate, subtherapeutic, and toxic levels, on top of analyzing the impact of the inadequacy of these serum levels on clinical outcomes, like development of AKI and mortality. Despite the literature about vancomycin being vast, there have been few studies to correlate serum levels with clinical outcomes.

A total of 225 patients were evaluated, but only 135 were included in the analysis. This reflects the difficulty of studying the role of nephrotoxicity of vancomycin, for it is questionable if high serum levels of vancomycin are the cause (due to elevated serum concentration) or consequence of AKI (accumulation of the drug due to the impaired renal function from other injuries), as covered by the consensus of the American Society of Health-System Pharmacists, the Infectious Society of America, and the Society of Infectious Diseases Pharmacists.[@CIT0011] Therefore, one of the exclusion criteria of this study was the presence of AKI before the use of vancomycin or at 48 hours after starting its use.

In sum, 75.6% of the patients had their antimicrobial doses adjusted, with the mean number of realized adjustments being 2±1.65. Iwamoto et al[@CIT0012] noticed that patients that were not submitted to monitoring of therapeutic concentrations of vancomycin presented a significant reduction in depuration values of creatinine and thus higher risk of nephrotoxicity than those that were monitored (OR 0.25, *p*\<0.05). Davis et al[@CIT0013] evaluated adherence to guidelines instituted by the consensus of 2009[@CIT0011] regarding the use of vancomycin, and showed that despite the recommendations, only 19% of institutions questioned claimed to use a standard definition to identify vancomycin-associated nephrotoxicity.

Despite having the availability to realize therapeutic monitoring of the drug, which is not unanimous in all centers, difficulties have been observed with reaching and sustaining adequate serum concentrations, due to factors related to collection, patients, and pharmacokinetic variation of the drug in septic patients.[@CIT0008] In our study, this difficulty was also present, with elevated rates of subtherapeutic and toxic concentrations.

The incidence of AKI found in this study was 27.4%, which happened on average 9 days after the start of usage of vancomycin, with mortality of 20.7%. Data from the literature suggest variable nephrotoxicity prevalence: from 5% to 40% in the presence of other nephrotoxins in concomitant use.[@CIT0011],[@CIT0014]--[@CIT0016] On Cox regression analysis, only the higher value of serum concentration between the fourth and sixth days was a factor associated with the development of AKI in this population, with serum concentration \>21.5 mg/L showing to be a good predictor of AKI, with an area under the curve of 0.8, sensitivity of 81.1%, specificity of 73.7%, and preceding the diagnoss of AKI by 3 days (AKI happened on average on the ninth day of use of vancomycin).

A prospective multicentric study conducted by Bosso et al[@CIT0017] evaluating 288 patients using vancomycin found an association between nephrotoxicity incidence and vancomycin concentrations, with AKI occurring in 29.6% of patients with serum concentrations of vancomycin \>15 mg/L and 8.9% of patients with vancomycin concentrations \<15 mg/L. Ten other studies reviewed by Gupta et al[@CIT0016] identified concentrations of vancomycin \>15 mg/L as a predictor of nephrotoxicity, with AKI incidence of 27%. As such, the ideal therapeutic concentrations aimed at preventing nephrotoxic AKI are questionable. On Cox regression analysis, the higher concentration of vancomycin between the fourth and sixth days was the only predictor of death in the population.

This study presents some limitations, such as the small sample obtained, reflecting the difficulty of studying nephrotoxicity; the data being obtained from a single center; the fact of bacterial vancomycin resistance not having being studied; and the role of serum concentration as a prognostic predictor of AKI (eg, gravity and necessity of acute renal support). Despite these limitations, it was the first study to present cutoff values with an objective of refining the use and monitoring of vancomycin in septic patients in clinical and surgical wards.

Conclusion {#S0005}
==========

This study showed that the prevalence of AKI associated with the use of serum concentration of vancomycin was elevated and that serum concentrations \>21.5 mg/L between the fourth and sixth days were an independent predictor of AKI, presenting sensitivity and specificity \>80% and preceding AKI diagnostis by at least 3 days. It was also shown to be associated with death on uni- and multivariate analysis, remaining the single predictor of death even after adjustment by the Cox model for the variables that also showed statistical significance. Therefore, early identification of serum concentrations of vancomycin can make adequate therapeutic interventions possible, eg, with adjustment of doses or administration intervals, with the goal of preventing AKI or modifying its natural history, resulting in a possible reduction in mortality.
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[^1]: **Notes:** \*Mean ± SD. Values in bold denote significance.

    **Abbreviations:** GFR, glomerular filtration rate; CKD, chronic kidney disease; CVD, cardiovascular disease; AKI, acute kidney injury.

[^2]: **Notes:** T0--T2, serum concentration between the start and the second day of usage of vancomycin (0--48 hours); T2--T4, serum concentration between the second and fourth days of usage of vancomycin (48--96 hours); T4--T6:, serum concentration between the fourth and sixth days of usage of vancomycin (96--144 hours); T6--T8, serum concentration between the sixth and eighth days of usage of vancomycin (144--192 hours). \*Mean ± SD. Values in bold denote significance.

    **Abbreviation:** AKI, acute kidney injury.

[^3]: **Notes:** T4--T6, serum concentration between the fourth and sixth days of usage of vancomycin (96--144 hours). Values in bold denote significance.

[^4]: **Notes:** \*Mean ± SD; ^\#^nonhormonal anti-inflammatory, amphotericin B, acyclovir, amycacin. Values in bold denote significance.

    **Abbreviations:** GFR, glomerular filtration rate; CKD, chronic kidney disease; CVD, cardiovascular disease; AKI, acute kidney injury.

[^5]: **Notes:** \*Mean ± SD. T0--T2, serum concentration between the start and second day of usage of vancomycin (0--48 hours); T2--T4: serum concentration between the second and fourth days of usage of vancomycin (48--96 hours); T4--T6: serum concentration between the fourth and sixth days of usage of vancomycin (96--144 hours); T6--T8: serum concentration between the sixth and eighth days of usage of vancomycin (144--192 hours). Values in bold denote significance.

[^6]: **Notes:** T4--T6, serum concentration between the fourth and sixth days of usage of vancomycin (96--144 hours). Values in bold denote significance.

[^7]: **Abbreviation:** AKI, acute kidney injury.
